Quoin Pharmaceuticals shares are trading higher after the company announced FDA clearance to recruit teen subjects into both of its ongoing Netherton Syndrome clinical studies.
Portfolio Pulse from Benzinga Newsdesk
Quoin Pharmaceuticals shares surged following the FDA's approval to include teenage subjects in its Netherton Syndrome clinical trials.
March 04, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quoin Pharmaceuticals received FDA clearance to include teenage subjects in its Netherton Syndrome clinical trials, positively impacting its stock.
The FDA's clearance for Quoin Pharmaceuticals to include teenage subjects in its Netherton Syndrome clinical trials is a significant regulatory milestone. This approval likely boosts investor confidence in the company's research capabilities and potential for future success, leading to a positive short-term impact on its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100